Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial
- Resource Type
- Article
- Source
- In
Lung Cancer April 2024 190 - Subject
- Language
- ISSN
- 0169-5002